The VICC.ORG Directory of Doctors, Healthcare Providers & Researchers
Ingrid A. Mayer, M.D., M.S.C.I.
See also:
- Breast Cancer Research Program
- Medicine: Hematology/Oncology
- BRET: Biomedical Research Education & Training Faculty Listing
- PubMed Listing of Dr. Mayer's Publications
Learn More About Ingrid A. Mayer's Specialties:
Assistant Professor of Medicine
Clinical Director, Breast Cancer Program
VICC Member
Medical Oncologist
- Appointments
615-322-2064
Physicians: 1-877-936-8422 - Clinical Trials Information
- Clinical Trials: 1-800-811-8480
- Online Self-Referral Form
- Other Telephone NumbersVanderbilt Breast Center One Hundred Oaks
615-322-2064; Referring Physicians: 615-343-9283
Office
615-936-3831 - FaxesVanderbilt Breast Center One Hundred Oaks Fax
615-343-7622
Office Fax
615-343-7602 - AddressesVanderbilt Breast Center One Hundred Oaks
719 Thompson Lane, Suite 25000
Nashville, TN 37204
Website
Office
Vanderbilt-Ingram Cancer Center
777 Preston Building
Nashville, TN 37232-6307
Profile
Dr. Ingrid Mayer graduated medical school in 1993 at the Federal University of Sao Paulo, Brazil. She completed her Internal Medicine Residency and Chief Residency in 1998 at the University of Illinois at Chicago, where she also did her Hematology/ Oncology Fellowship training from 1998 through 2001.
Read more ....
Dr. Ingrid Mayer graduated medical school in 1993 at the Federal University of Sao Paulo, Brazil. She completed her Internal Medicine Residency and Chief Residency in 1998 at the University of Illinois at Chicago, where she also did her Hematology/ Oncology Fellowship training from 1998 through 2001. During this time, she worked in the laboratory setting with MAPK signaling pathway in Chronic Myelogenous Leukemia, for which she received an American Society of Clinical Oncology (ASCO) Young Investigator Award.
In 2003, Dr. Mayer became an Assistant Professor of Medicine in the Division of Hematology/ Oncology at the Vanderbilt University School of Medicine, where she completed a Master of Science in Clinical Investigation (MSCI) Program in May 2006. She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens/targets in breast cancer tumor samples. She has intensively worked in translational projects related to targeted therapies in breast cancer, obtaining a Pilot Project from the Breast Cancer SPORE in 2005. She has also obtained a Breast Cancer Research Foundation – American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER+/HER2+ breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also!
co-Leader in three of the four research projects of the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Director).
Dr. Mayer is a key component of the Vanderbilt-Ingram Cancer Center (VICC) Breast Cancer Program, where her role is to implement and conduct investigator-initiated, mechanism-based clinical and translational trials in breast cancer, focusing in novel diagnostic and therapeutic approaches. Administratively, she directs the Clinical Core of the VICC Breast Cancer SPORE. She is a member of the Eastern Cooperative Oncology Group (ECOG) Breast Committee, the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, and had served in the American Society of Clinical Oncology (ASCO) Scientific Review Committee for two years.
Education
- Doctor of Medicine
Federal University of Sao Paulo, Sao Paulo, Brazil
February, 1988 - December, 1993 - University of Miami School of Medicine, Miami, FL
Latin American Training Program
February - June 1994 - Residency, Internal Medicine
University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
July 1994 - June 1997 - Chief Residency, Internal Medicine
University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
July 1997 - June 1998 - Fellowship, Hematology/OncologyUniversity of Illinois at Chicago Affiliated Hospitals, Chicago, IL
July 1998 - June 2001 - Master of Science in Clinical Investigation
Vanderbilt University School of Medicine, Nashville, TN
September 2004 - September 2006
Research Specialty
Breast Cancer - Targeted Therapies
Research Description
My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection.
My role as a clinical investigator are as follows:
1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials.
2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies.
3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer .
My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies.
Examples of some of my investigator-initiated clinical trials include:
VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer
VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer
VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaâ„¢, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer
VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer
VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Clinical Interest
Dr. Mayer is a medical oncologist who specializes in breast cancer. Her research focus is clinical and translational correlative studies in Breast Cancer. She is primarily involved with development of clinical trials addressing novel effective combinations of chemotherapy and biological agents for treatment and prevention, and identification of new markers and predictors of disease.
Her research endeavors have been focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. She has been developing hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems. This will facilitate the process of identifying new molecular targets with prognostic and therapeutic value, and in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers.
Clinical Research Description
My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection. My role as a clinical investigator are as follows: 1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials. 2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies. 3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer . My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies. Examples of some of my investigator-initiated clinical trials include: VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaâ„¢, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Publications
- Mayer, IA, Arteaga, CL Does lapatinib work against HER2-negative breast cancers. Clin Cancer Res, 16(5), 1355-7, 2010.
- Bauer, JA, Chakravarthy, AB, Rosenbluth, JM, Mi, D, Seeley, EH, De Matos Granja-Ingram, N, Olivares, MG, Kelley, MC, Mayer, IA, Meszoely, IM, Means-Powell, JA, Johnson, KN, Tsai, CJ, Ayers, GD, Sanders, ME, Schneider, RJ, Formenti, SC, Caprioli, RM, Pietenpol, JA Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res, 16(2), 681-90, 2010.
- Li, X, Dawant, BM, Welch, EB, Chakravarthy, AB, Freehardt, D, Mayer, I, Kelley, M, Meszoely, I, Gore, JC, Yankeelov, TE A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging, 27(9), 1258-70, 2009.
- Mayer IA, Means-Powell J, Shyr Y, Arteaga CL "A phase Ib trial of Erlotinib, and EGFR inhibitor, and Everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer." 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3094, 2009.
- Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA. "A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer.." 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3093, 2009.
- Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Jahanzeb, M, Kiel, K, Ljung, BM, Marcom, PK, Mayer, IA, McCormick, B, Nabell, LM, Pierce, LJ, Reed, EC, Smith, ML, Somlo, G, Theriault, RL, Topham, NS, Ward, JH, Winer, EP, Wolff, AC, , Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 7(2), 122-92, 2009.
- Pohlmann, PR, Mayer, IA, Mernaugh, R Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res, 15(24), 7479-7491, 2009.
- Planey, CR, Welch, EB, Xu, L, Chakravarthy, AB, Gatenby, JC, Freehardt, D, Mayer, I, Meszeoly, I, Kelley, M, Means-Powell, J, Gore, JC, Yankeelov, TE Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging, 30(1), 121-34, 2009.
- Mayer, IA Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer, 9 Suppl 2S50-7, 2009.
- Guix, M, Mayer, IA, Meszoely, IM, Arteaga, CL Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res, 10 Suppl 4S25, 2008.
- Guix, M, Granja, Nde M, Meszoely, I, Adkins, TB, Wieman, BM, Frierson, KE, Sanchez, V, Sanders, ME, Grau, AM, Mayer, IA, Pestano, G, Shyr, Y, Muthuswamy, S, Calvo, B, Krontiras, H, Krop, IE, Kelley, MC, Arteaga, CL Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol, 26(6), 897-906, 2008.
- Yankeelov, TE, Lepage, M, Chakravarthy, A, Broome, EE, Niermann, KJ, Kelley, MC, Meszoely, I, Mayer, IA, Herman, CR, McManus, K, Price, RR, Gore, JC Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 25(1), 1-13, 2007.
- Chakravarthy, AB, Kelley, MC, McLaren, B, Truica, CI, Billheimer, D, Mayer, IA, Grau, AM, Johnson, DH, Simpson, JF, Beauchamp, RD, Jones, C, Pietenpol, JA Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res, 12(5), 1570-6, 2006.
- Rouch D, Mayer I, Truica C "Barriers to chemoprevention of breast cancer with tamoxifen." American Society of Clinical Oncology Proceedings, 41th Annual Meeting abst 1010, 2005.
- Mayer IA "Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer." Cytokines and Cancer, chapter 10(Platanias LC (ed). 2005 Springer Science + Business Media, Inc.), 243, 2005.
- Mayer, IA Targeting cytokine receptors and pathways in the treatment of breast cancer. Cancer Treat Res, 126243-62, 2005.
- Yamaguchi NH, Mayer IA, Malzyner A, Andrade CJC, Murad AM, Giglio AD, Cardoso H. A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors. ASCO Proceedings, 40th Annual Meeting(), Abstract No 3086, 2004.
- Chakravarthy B, Kelley M, McLaren B, Truica C, Mayer I, Brown C, Johnson K, Simpson J, Billheimer D, Pietenpol JA Developing markers of therapeutic response using serial core biopsies to paclitaxel/radiation in stage II/III breast cancer. Breast Cancer Research and Treatment, supplement 1 (San Antonio Breast Cancer Symposium ¿ 27th Annual Meeting - Special Issue)(88), S50 (abstract 1028), 2004.
- Costa FP, Schemerling R, Costa OF, Costa PA, Albertotti C, Martins S, Buzaid AC, Maluf F, Mayer I, Marques R Intra-hepatic lipiodol I-131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis. ASCO Proceedings, 40th Annual Meeting(), Abstract No 4133, 2004.
- Mayer IA "Locally Advanced Breast Cancer." Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition(), chapter 2, 2004.
- Mayer IA "Metastatic Breast Cancer." Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition(), chapter 3, 2004.
- Costa FC, Marques RJ, Mayer IA, Maluf FC, Martins SC, Cutait R, Buzaid AC Irinotecan, Oxaliplatin and Raltitrexed every two weeks in untreated metastatic colorectal cancer patients. ASCO Proceedings , 38th Annual MeetingAbstract No 2348, 2002.
- Grumbach, I M, Mayer, I A, Uddin, S, Lekmine, F, Majchrzak, B, Yamauchi, H, Fujita, S, Druker, B, Fish, E N, Platanias, L C Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br J Haematol, 112(2), 327-36, 2001.
- Mayer, I A, Verma, A, Grumbach, I M, Uddin, S, Lekmine, F, Ravandi, F, Majchrzak, B, Fujita, S, Fish, E N, Platanias, L C The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem, 276(30), 28570-7, 2001.
- Mayer IA, Grumbach IM, Fujita S, Uddin S, Platanias LC "Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia." Blood, 96(11), Abstract No 1500, 2000.
- Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC The Rac1/p38 Map kinase pathway is required for IFN-alpha dependent transcriptional activation but not serine phosphorylation of STAT-proteins. J Biol Chem, 275(36), 27634-40, 2000.
You do not have JavaScript enabled. This site works better with JavaScript turned on.
